Supplementary Table 1. Study Population, CT Technique and Study Observers Details

Supplementary Table 1. Study population, CT technique and study observers details.

Referral Hospitals / CT scanner model / Contrast enhanced CT parameters / HRCT parameters / Senior radiologist* / Junior radiologist* / CT scans for suspected pulmonary embolism / CT scans for lung cancer staging / HRCT for lung fibrosis
1 / 64-detector row (Sensation, Siemens Medical Solutions, Forchheim, Germany / 120 kVp
120-140 effective mAs
Care Dose 4D (on)
Algorithm: B30f
Thickness: 1.5-2.5 mm
Interval: 1-2mm / 120 kVp
120 effective mAs
Care Dose 4D (on)
Algorithm: B70f
Thickness: 1mm
Interval: 1mm
20/40 (50%) supine decubitus / 32 / 4 / 43 / 40 / 40
2 / 16-detector row (LightSpeed 16, GE Healthcare, Milwaukee, Wis) / 120
kVP120
-140
effective
mAs
Aut
omA (on)
Alg
orithm:
standard
Thi
ckness: 1.25-
2.5 mm
Inte
rval: 1.25-
2.5 mm / 120
kVp
120
effective
mAs
Car
e Dose 4D
(on)
Alg
orithm: bone
Thi
ckness:
1mm
Inte
rval: 1mm / 17 / 3 / 39 / 40 / 41
3 / 4-detector row (Somatom Volume Zoom, Siemens Medical Solutions, Forchheim, Germany) / 140
kVp
120
effective
mAs
Alg
orithm:
B10
f
Thi
ckness:
1.5
mm
Inte
rval: 1.5mm / 140
kVp
120
effective
mAs
Alg
orithm:
B70
f
Thi
ckness:
1.2
5 mm
Inte
rval: 1.5 mm / 18 / 3 / 40 / 40 / 40
4 / 16-detector row (LightSpeed 16, GE Healthcare, Milwaukee, Wis) / 120
kVp
120
-140
effective
mAs
Aut
omA (on)
Alg
orithm:
standard
Thi
ckness: 1.25-
2.5 mm
Inte
rval: 1.25-
2.5 mm / 120
kVp
120
effective
mAs
Aut
omA (on)
Alg
orithm: bone
Thi
ckness: 1.25
mm
Inte
rval: 1.25
mm / 30 / 2 / 21 / 27 / 42

Notes: numbers in brackets refer to the percentage of the whole study population; * = numbers refer to the years of experience in chest imaging

Supplementary Table 2. Comparison between the study reviewers and the local radiologists evaluations in HRCT studies obtained for patients with interstitial lung disease.

Cardiovascular findings / Study reviewers consensus evaluation (%) / Local radiologists (%) / Cardiovascular findings percentage missed by the local radiologists / p-value@
CAC
Any / 127 (79) / 43 (26.7)° / 52.3 (45.9-54.3) / <0.0001
A (focal) / 58 / NA / NA / NA
B (diffuse) / 69 / NA / NA / NA
Valvular calcification
Any / 107 (66.4) / 61 (37.9)° / 28.5 (18.2-36.6) / <0.0001
Aortic leaflets / 100 (62.1) / 22 (13.6) / 48.5 (40.3-53.1) / <0.0001
Mitral leaflets / 37 (22.2) / 8 (4.9) / 17.3 (12.1-19) / <0.0001
Ascending aorta calcification / 51 (31.7) / 42 (26.1) / 5.6 (-3.7-14.2) / 0.3
Left ventricle myocardial calcification* / 2 (1.2) / 0 (0) / 1.2 (-0.7-1.2) / 0.5
Left papillary muscles calcification* / 3 (1.9) / 0 (0) / 1.9 (-0.7-1.8) / 0.2
Pericardial calcification* / 0 / 1 (0.6) / NA / NA
Low (fatty) attenuation areas in the left ventricle wall* / 5 (3.1) / 0 (0) / 3.1 (-0.1-3.1) / 0.05
Ascending aorta enlargement (>40 mm)* / 17 (10.6) / 12 (7.4) / 3.2 (-0.3-8.3) / 0.4
Main pulmonary artery enlargement / 57 (35.4) / 60 (37.3) / -1.9 (-6.8-10.2) / 0.8
Pericardial effusion
Any / 15 (9.3) / 6 (3.7)° / 5.6 (0.7-7.7) / 0.02
Minimal / 12 / NA / NA / NA
Large* / 3 / NA / NA / NA
Pericardial thickening (smooth or nodular)* / 1 (0.6) / 0 / 0.6 (-1-1) / 1

Notes.° = CAC subtypes, individual valvular calcification and pericardial effusion subtypes were grouped for the study reviewers scores to be compared with the original radiology reports; * = significant cardiovascular findings; @ p-values are obtained through the McNemar test.

Supplementary Table 3. Comparison between the study reviewers and the local radiologists evaluations in CT studies with and without contrast medium obtained for patients with suspected pulmonary embolism and lung cancer staging.

Cardiovascular findings / Study reviewers consensus evaluation (%) / Local radiologists (%) / Cardiovascular findings percentage missed by the local radiologists / p-value@
CAC
Any / 195 (68.2) / 40 (14)° / 54.2 (51.6-54.2) / <0.0001
A (focal) / 73 / NA / NA
B (diffuse) / 122 / NA / NA
Valvular calcification
Any / 158 (55.2) / 59 (20.6)° / 34.6 (28.5-39.1) / <0.0001
Aortic leaflets / 142(49.6) / 19 (6.6) / 45 (38.5 -45.3) / <0.0001
Mitral leaflets / 58 (20.3) / 3 (1) / 19.3 (16.2-19.8) / <0.0001
Ascending aorta calcification / 123 (43) / 55 (19.2) / 23.8 (17.5-28.7) / <0.0001
Left ventricle myocardial calcification* / 1 (0.3) / 0 (0) / 0.3 (-0.2-0.3) / NA
Left papillary muscles calcification* / 1 (0.3) / 0 (0) / 0.3 (-0.2-0.3) / NA
Pericardial calcification* / 4 (1.4) / 0 / 1.4 (-0.4-1) / 0.2
Low (fatty) attenuation areas in the left ventricle wall* / 5 (1.7) / 0 (0) / 1.7 (-0.1-1.7) / 0.05
Ascending aorta enlargement (>40 mm)* / 27 (9.4) / 17 (5.9) / 3.5 (0.2-6.3) / 0.05
Main pulmonary artery enlargement / 46 (16.1) / 24 (8.4) / 7.7 (0-8.2) / 0.05
Pericardial effusion
Any / 33 (11.5) / 29 (10.3)° / 1.2 (-0.8-1.6) / 0.09
Minimal / 6 (2.1) / NA / NA / NA
Large* / 15 (5.2) / NA / NA / NA
Pericardial thickening (smooth or nodular)* / 6 (2.1) / 4 (1.4) / 0.7 (-0.8-1.7) / 0.4
Cardiac chamber enlargement*
LA / 17 (5.9) / 8 (2.8) / 3.1 (0.01-5.1) / 0.05
RA / 26 (9.1) / 9 (3.1) / 5.9 (2.9-7.1) / 0.0002
LV / 34 (11.9) / 9 (3.1) / 8.7 (5-10.7) / <0.0001
RV / 20 (7) / 17 (5.9) / 1.1 (-2.3-4.13) / 0.7
Left ventricle myocardium hypertrophy* / 58 (20.3) / 1 (0.3) / 19.9 (17.4-19.9) / <0.0001
Left ventricle aneurysm* / 8 (4) / 1 (0.5) / 3.5 (0.6-3.5) / 0.01
Filling defect in any cardiac chamber (mass or thrombus) * / 7 (2.4) / 2 (0.7) / 1.1 (-0.2-1.5) / 0.12
Others* / 6 (2.3) / 0 / 2.3 (0.8-2.3) / 0.002